ORIGYN-FOUNDATION
22.4.2022 18:16:12 CEST | Business Wire | Press release
ORIGYN Foundation, the Swiss non-profit foundation dedicated to identifying, authenticating and unlocking the powers of ownership for objects of value, has announced a partnership with UEFA Foundation for Children. ORIGYN and the UEFA Foundation for Children will partner to create a unique selection of collectibles and NFTs that directly benefits the foundation’s mission to fund children’s rights in areas such as health, education and integration.
As a key component of ORIGYN’s ‘NFTs for Good’ initiative, ORIGYN and UEFA Foundation for Children will create a limited collection of physical collectibles. A corresponding digital twin will be created for each of the one-of-a-kind memorabilia, including one of the toss coins that helped determine the outcome of the UEFA EURO 2020 Final between England and Italy.
“We are thrilled to partner with ORIGYN to bring these important items to the world stage and for the benefit of The UEFA Foundation for Children,” said Urs Kluser, General Secretary for the UEFA Foundation for Children. “We share a united vision of leveraging next-generation technology such as NFTs to raise money for children and world citizens across the globe. There is no better collective mission.”
ORIGYN is the only platform that ties the digital certificate to the world’s most valuable physical artifacts and collectibles. These digital twins are non-fungible, unique and, in many cases, tied to a corresponding physical object. The iconic coin will be minted by ORIGYN into a digital twin NFT and auctioned off together with the physical coin in the second quarter of 2022, alongside other rare collectibles from the foundation.
“We’re incredibly fortunate to have partnered with a foundation that shares a passion for helping children around the world. NFTs are a global technology and should benefit all,” said Daniel Haudenschild , CEO of ORIGYN Enterprise.
This series of unique sports collectibles from the UEFA Foundation for Children, as well as their corresponding digital twin NFTs, will exclusively appear on the ORIGYN-powered consumer marketplace, Impossible Things. Impossible Things will allow collectors to buy, sell and experience unique and authenticated collectibles.
The Impossible Things marketplace will launch in Q2 of 2022 with an Impossible Pass, providing holders priority access to all of the limited collection drops to appear on the marketplace.
“Leveraging ORIGYN’s proprietary technology and the unique consumer-friendly platform at Impossible Things enables us to support causes like The UEFA Foundation for Children, as well as collectors and investors who demand authenticity from the goods they purchase and the cultures that surround them,” said Tom Flanagan, Managing Director of ORIGYN Collectibles.
About the ORIGYN Foundation:
The Swiss non-profit foundation ORIGYN uses intelligent technologies, including computer vision and artificial intelligence, on decentralized computing to identify, authenticate and unlock the powers of ownership for objects of value. As the first digital certification platform built on the Internet Computer (IC), ORIGYN and its verticals generate new forms of value for some of the largest consumer asset classes in the world, including art, collectibles, digital media and luxury goods. Founded in Neuchâtel, Switzerland in October of 2020, ORIGYN operates globally in major technology and blockchain hubs around the world. The foundation’s utility token, OGY, is set to become publicly tradable in the second quarter of 2022. For more information, visit origyn.ch .
ORIGYN Foundation: Website Twitter Telegram LinkedIn Facebook Medium Instagram
For more information about Impossible Things, visit here .
About The UEFA Foundation for Children:
The UEFA Foundation for Children aims to help children and defend their rights, for example through sport and football. It provides support in the areas of health, education, access to sport, personal development, integration of minorities and employability. The Foundation, a public utility body under Swiss law, was created and started its activities on April 24, 2015. The foundation currently invests in 180 projects and has so far funded more than 400 projects in 130 countries worldwide. More than 1.8 million children have already benefited from the foundation's work since its creation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220422005488/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom